To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Vitamin D and growth horm… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Vitamin D and growth hormone treatment.

Conference contribution
Authors Björn Andersson
Diana Swolin-Eide
Published in 9th Joint meeting of Paediatrics Endocrinology, Milan , Italy.
Volume 19-22
Issue Sept
Pages P2-d2-836
Publication year 2013
Published at Institute of Clinical Sciences, Department of Pediatrics
Pages P2-d2-836
Language en
Subject categories Orthopedics, Pediatrics


Background: Living in Sweden which is in the northern part of the world, above 35° of latitude implies a major risk of vitamin D deficiency. Prepubertal children show a marked seasonal variation in growth parallel to hours of sunshine. Vitamin D shows a similar pattern with the highest levels during late summer. Growth hormone (GH) promotes longitudinal growth in short prepubertal children. Objective and hypotheses: The aim was to study the influence of seasonal variation in vitamin D levels on pretreatment growth and first year growth response to GH treatment. Methods: The study group consisted of 279 short prepubertal children, 223 boys age 9.08±2.6 SD, 56 girls age 7.79±1.65, belonging to registered clinical trials in Sweden. GH was given in the range 17-100 µg/kg/day, mean 0.42 µg/ kg/day. 82 children were GHD (GHmaxAITT/24h profile ≤ 10 µg/L). n=24/104 (23%), of whom n=63/104 (60.5%) had Isolated GHD whereas n=41/104 (39.4%) had Multiple Pituitary Hormone Deficiency (MPHD). Median age at CO-GHD diagnosis was 11.2yr (0.3 -16.6) with initial GH peak 2.2µg/l (0.1 - 6.5); and initiation of GH therapy at 9.5 (0.4 -16.9) yrs. Result: At final height, n=60/104(57.6%) CO-GHD adult were re-evaluated at a median age 18.2 yr (15-27.5), 0.5 (0.1-12) years after withdrawal of GH therapy at age 16 (9 -21) yr. Median duration of treatment was 7.6 (0.4-16.3)yr. At retesting median GH peak was 1.7µg/l (0.1-23.7) and IGF1 level 79ug/l (15-560). Of those re-evaluated 52/60(86.8%) remained GHD and were eligible for adult GH replacement, with 45/60(75%) re-starting GH and 7/60(11.6%) declining GH. The remaining CO-GHD treated patients n=44/104(42.3%) were not re-evaluated either because they were transferred to adult services without re-evaluation (n=21), stopped treatment without reevaluation (n=6), were lost to follow up while on treatment (n=10), or had missing data in (n=7). Conclusions: A substantial proportion of CO-GHD patients remain GHD and most opt for GH therapy as adults, yet not all are re-evaluated. A consensus standardised pathway for re-evaluation of the GH axis between paediatric and adult services has not yet been reached. There is a need to study

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?